60 Einträge gefunden

1. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

   1. Reich, K
   2. Gordon, K B
   3. Strober, B
   4. Langley, R G
   5. Miller, M
   6. Yang, Y-W
   7. Shen, Y-K

   2022 - Forschungsinformationssystem des UKE
2. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3

   1. Reich, K
   2. Iversen, L
   3. Puig, L
   4. Lambert, J
   5. Mrowietz, U
   6. Kaplan Saday, K
   7. Warren, R B

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

   1. Reich, K
   2. DeLozier, A M
   3. Nunes, F P
   4. Thyssen, J P
   5. Eichenfield, L F
   6. Wollenberg, A
   7. Ross Terres, J A

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

   1. Gordon, K B
   2. Reich, K
   3. Crowley, J J
   4. Korman, N J
   5. Murphy, F T
   6. Poulin, Y
   7. Spelman, L

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

   1. Warren, R B
   2. Hansen, J B
   3. Reich, K
   4. Paul, C
   5. Puig, L

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach

   1. Tsakok, T
   2. Rispens, T
   3. Spuls, P
   4. Nast, A
   5. Smith, C
   6. Reich, K

   2021 - Forschungsinformationssystem des UKE
7. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study

   1. Maul, J-T
   2. Augustin, M
   3. Sorbe, C
   4. Conrad, C
   5. Anzengruber, F
   6. Mrowietz, U
   7. Reich, K

   2021 - Forschungsinformationssystem des UKE
8. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study

   1. Reich, K
   2. Körber, A
   3. Mrowietz, U
   4. Sticherling, M
   5. Sieder, C
   6. Früh, J
   7. Bachhuber, T

   2021 - Forschungsinformationssystem des UKE
9. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

   1. Bieber, T
   2. Thyssen, J P
   3. Reich, K
   4. Simpson, E L
   5. Katoh, N
   6. Torrelo, A
   7. De Bruin-Weller, M

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
10. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

    1. Reich, K
    2. Mrowietz, U
    3. Menter, A
    4. Griffiths, C E M
    5. Bagel, J
    6. Strober, B
    7. Nunez Gomez, N

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
11. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

    1. Warren, R B
    2. Carrascosa, J M
    3. Fumero, E
    4. Schoenenberger, A
    5. Lebwohl, M G
    6. Szepietowski, J C
    7. Reich, K

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
12. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

    1. Reich, K
    2. Gordon, K B
    3. Strober, B E
    4. Armstrong, A W
    5. Miller, M
    6. Shen, Y K
    7. You, Y

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
13. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

    1. Pinter, A
    2. Hoffmann, M
    3. Reich, K
    4. Augustin, M
    5. Kaplan, K
    6. Gudjónsdóttir, S D
    7. Delvin, T

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
14. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study

    1. Reich, K
    2. Sullivan, J
    3. Arenberger, P
    4. Jazayeri, S
    5. Mrowietz, U
    6. Augustin, M
    7. Elewski, B

    2021 - Forschungsinformationssystem des UKE
15. Network meta-analyses in psoriasis: overview and critical discussion

    1. Augustin, M
    2. Valencia López, Maria José
    3. Reich, K

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
16. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

    1. Blauvelt, A
    2. Paul, C
    3. van de Kerkhof, P
    4. Warren, R B
    5. Gottlieb, A B
    6. Langley, R G
    7. Brock, F

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
17. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment

    1. Leutz, A
    2. Pinter, A
    3. Thaçi, D
    4. Augustin, M
    5. Schuster, C
    6. Fotiou, K
    7. Hundemer, H P

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
18. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3

    1. Reich, K
    2. Hansen, J B
    3. Puig, L
    4. Konstantinou, M P
    5. Warren, R B

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
19. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS)

    1. Wilsmann-Theis, D
    2. Kromer, C
    3. Gerdes, S
    4. Linker, C
    5. Magnolo, N
    6. Sabat, R
    7. Reich, K

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
20. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)

    1. Gordon, K B
    2. Warren, R B
    3. Gottlieb, A B
    4. Blauvelt, A
    5. Thaçi, D
    6. Leonardi, C
    7. Poulin, Y

    2021 - Forschungsinformationssystem des UKE - frei zugänglich